Globeflex Capital L P Trims Position in ICON Public Limited (NASDAQ:ICLR)

Globeflex Capital L P decreased its position in shares of ICON Public Limited (NASDAQ:ICLR - Free Report) by 8.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 48,363 shares of the medical research company's stock after selling 4,321 shares during the quarter. ICON Public accounts for approximately 0.9% of Globeflex Capital L P's investment portfolio, making the stock its 25th largest holding. Globeflex Capital L P owned 0.06% of ICON Public worth $10,142,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Natixis Advisors LLC boosted its holdings in ICON Public by 6.7% in the fourth quarter. Natixis Advisors LLC now owns 177,761 shares of the medical research company's stock valued at $37,279,000 after purchasing an additional 11,177 shares during the last quarter. Private Trust Co. NA lifted its holdings in shares of ICON Public by 48.8% in the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company's stock valued at $52,000 after buying an additional 82 shares during the period. Transcend Capital Advisors LLC purchased a new stake in shares of ICON Public in the fourth quarter worth about $229,000. FDx Advisors Inc. grew its holdings in ICON Public by 13.6% during the fourth quarter. FDx Advisors Inc. now owns 3,527 shares of the medical research company's stock worth $740,000 after acquiring an additional 422 shares during the period. Finally, Kornitzer Capital Management Inc. KS raised its position in ICON Public by 40.6% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company's stock valued at $20,363,000 after acquiring an additional 28,050 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company's stock.

Remove Ads

ICON Public Price Performance

ICLR stock traded down $1.55 during midday trading on Wednesday, reaching $184.48. The stock had a trading volume of 928,999 shares, compared to its average volume of 828,320. ICON Public Limited has a 52-week low of $174.93 and a 52-week high of $347.72. The company has a market cap of $14.90 billion, a price-to-earnings ratio of 19.36, a price-to-earnings-growth ratio of 1.86 and a beta of 1.21. The company's fifty day simple moving average is $194.84 and its 200 day simple moving average is $228.47. The company has a current ratio of 1.26, a quick ratio of 1.34 and a debt-to-equity ratio of 0.36.

ICON Public (NASDAQ:ICLR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.01. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. The firm had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.04 billion. As a group, sell-side analysts predict that ICON Public Limited will post 13.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ICLR shares. Citigroup dropped their price objective on shares of ICON Public from $300.00 to $290.00 and set a "buy" rating on the stock in a research note on Monday, January 6th. JPMorgan Chase & Co. dropped their price target on shares of ICON Public from $280.00 to $265.00 and set an "overweight" rating on the stock in a research report on Monday, February 3rd. Robert W. Baird decreased their price objective on shares of ICON Public from $221.00 to $203.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Truist Financial dropped their target price on ICON Public from $284.00 to $262.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. Finally, Barclays reduced their price target on ICON Public from $275.00 to $240.00 and set an "overweight" rating for the company in a report on Friday, February 21st. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $279.17.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.